Peptide receptor radionuclide therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) - Evaluation of treatment response and hemato- and nephrotoxicity
- Conditions
- Gastroenteropancreatic neuroendocrine Tumors.C15-C26Malignant neoplasms of digestive organs
- Registration Number
- DRKS00008976
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 63
Inclusion Criteria
Patients suffering from gastroenteropancreatic neuroendocrine tumors treated by PRRT at the Department of Nuclear Medicine since 2009 will be selected.
Exclusion Criteria
Patients who received less than 3 cycles of PRRT or patients with incomplete data sets.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of significant factors influencing nephro- and hematotoxicity of PRRT in patients with gastroenteropancreatic neuroendocrine tumors.
- Secondary Outcome Measures
Name Time Method Assessment of clinical response to PRRT in patients with gastroenteropancreaticneuroendocrine tumors .